Antibody Discovery News and Research

RSS

FairJourney Bio delivers antibody engineering for novel tumor-conditional IL-12 therapeutic approach that unlocks the potential of localized cytokine activation

FairJourney Bio ("FJBio"), a global antibody discovery expert, today announced the publication of a peer-reviewed study in mAbs describing a novel approach with the potential to improve the therapeutic window of IL-12, a potent anti-tumor cytokine.

From FairJourney Biologics 20 Aug 2026

New antibody-specific AI framework accelerates discovery of therapeutic drugs

Designing an effective antibody drug is like searching for the right key in a warehouse of locks. Scientists may begin with millions-or even billions-of antibody candidates, but only a tiny fraction will recognize and bind tightly to the disease target.

13 Aug 2026

Leerink Partners report names Carterra a core enabler of the $7 B "Lab-in-the-Loop" antibody discovery market

Carterra®, a leading provider of high-throughput surface plasmon resonance (HT-SPR) platforms for antibody and small molecule discovery, today highlighted new research from Leerink Partners identifying Carterra as a key enabling technology in the fast-growing market for AI-driven biologics drug discovery.

From Carterra Inc. 27 Jul 2026

Fairjourney Bio announces scientific program and leadership for The Antibody Series 2026

FairJourney Bio ("FJBio"), a global antibody discovery expert, has announced the program for The Antibody Series (TAS) 2026, which will explore how insights from natural antibody repertoires, advances in computational design, and novel engineering strategies are transforming the discovery and development of antibody therapeutics.

From FairJourney Biologics 21 Jul 2026

FairJourney Bio and AbTherx partner to offer fully integrated antibody discovery

FairJourney Bio (“FJBio”), a global antibody discovery expert, has entered a partnership with AbTherx, Inc. to bring transgenic mouse-based antibody discovery in-house. The agreement gives the Company access to AbTherx’s Atlas™ Full Human Diversity (FHD) and Common Light Chain (cLC) mouse technologies, completing a discovery route that partners can now run end to end entirely within FJBio’s integrated workflow.

From FairJourney Biologics S.A. 24 Jun 2026

Sino Biological launches XPressMAX™ Cell-Free Protein Synthesis Kit, accelerating AI-powered high-throughput antibody drug discovery

Sino Biological, Inc., a global leader in recombinant technology, is proud to announce the launch of its innovative XPressMAX™ Cell-Free Protein Synthesis Kit (Cat#: CFKIT02) , a cutting-edge solution designed to supercharge artificial intelligence (AI)-driven high-throughput screening pipelines for antibody drug discovery.

From Sino Biological Inc. 20 May 2026

AI-based generative framework create all-atom models of proteins in motion

Many drug and antibody discovery pathways focus on intricately folded cell membrane proteins. When molecules of a drug candidate bind to these proteins, like a key going into a lock, they trigger chemical cascades that alter cellular behavior.

13 May 2026

Nuclera launches antibody triage service to advance AI-driven antibody discovery

Nuclera, the biotechnology company enabling rapid access to high-quality proteins, today announced the launch of its antibody screening service to streamline the transition from antibody hit generation to lead selection.

From Nuclera 11 May 2026

FairJourney Bio opens Cryo-EM structural biology facility in San Diego

FairJourney Bio (FJBio), a global antibody discovery contract research organization (CRO), today announced the opening of its advanced cryo-electron microscopy (cryo-EM) structural biology facility in San Diego, California.

From FairJourney Biologics S.A. 13 Apr 2026

Nasal COVID vaccine boost increases IgA responses linked to variant neutralisation

Intranasal boosting after prior intramuscular COVID vaccination induced strong mucosal IgA responses in a small human cohort. These antibodies showed markedly enhanced neutralising activity against Omicron variants and evidence of immune memory reprogramming toward mucosal protection.

15 Feb 2026

FairJourney Bio launches cryo-EM services with advanced laboratories in San Diego, USA

FairJourney Bio (FJBio), a leading global provider of antibody discovery and development services, today announced the expansion of its portfolio with the launch of state-of-the-art cryo-electron microscopy (cryo-EM) services, supported through the Company's advanced laboratories in San Diego, CA.

12 Jan 2026

Breakthrough in FcγRI inhibition opens path to safer autoimmune therapies

An international research group directed by UMC Utrecht have developed and characterized two first-in-class antibodies that specifically block the high-affinity IgG receptor FcγRI.

19 Nov 2025

AI and protein language models can accelerate the design of antiviral antibodies

Artificial intelligence (AI) and "protein language" models can speed the design of monoclonal antibodies that prevent or reduce the severity of potentially life-threatening viral infections, according to a multi-institutional study led by researchers at Vanderbilt University Medical Center.

5 Nov 2025

GemPharmatech collaborates with MSK Cancer Center to accelerate discovery of therapeutic antibodies

GemPharmatech, a global leader in preclinical research solutions and genetically-engineered mouse models, today announced a collaboration with Memorial Sloan Kettering Cancer Center (MSK) to accelerate the discovery of new therapeutic antibodies.

23 Oct 2025

Antibody discovery could provide new treatment options for aggressive breast cancers

A new potential antibody therapy strategy which restricts the growth of treatment-resistant breast cancers has been developed by scientists.

23 Oct 2025

Abselion introduces Protein G Total Antibody Quantification Kit

Abselion, a pioneering life sciences technology company focused on simplifying biomolecule quantification, today announced the launch of its Protein G Total Antibody Quantification Kit.

From Abselion 22 Sep 2025

Novel method accurately identifies therapeutic antibodies to treat infectious diseases

Scientists at Scripps Research have developed a novel method that uses artificial intelligence (AI) and advanced imaging techniques to more accurately and efficiently identify therapeutic antibodies to treat infectious diseases.

10 Sep 2025

Researchers find plasma donors with broad malaria protection

Malaria, caused by Plasmodium falciparum, remains a major global health threat, claiming 600,000 lives annually, mostly young children in sub-Saharan Africa. Immunity to severe malaria develops after repeated infections and is mediated by antibodies blocking the parasite's highly diversified PfEMP1 adhesion proteins from binding to the human endothelial protein C receptor (EPCR) on blood vessel walls.

19 Aug 2025

New microchip tracks antibody-virus interactions from a single drop of blood

A new microchip invented by Scripps Research scientists can reveal how a person's antibodies interact with viruses-using just a drop of blood.

12 Jul 2025

Vanderbilt and Parse Biosciences team up to develop antibody treatments for measles

Vanderbilt University Medical Center and Parse Biosciences, an innovator in single-cell sequencing, are collaborating on a new treatment to help unvaccinated measles victims, as the U.S. measles outbreak has now reached its highest case count in 30 years.

8 Jul 2025